BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, April 25, 2024
Home
»
Newsletters
» BioWorld
BioWorld
May 11, 2004
View Archived Issues
Guilford Begins Phase III Program For Aquavan Injection In Sedation
Guilford Pharmaceuticals Inc. on Monday said it initiated a Phase III development program for Aquavan Injection, a candidate for procedural sedation. (BioWorld Today)
Read More
Cell Genesys Receives GVAX SPA For Phase III Prostate Cancer Trial
Read More
Peptimmune Gets License To Obesity Drug From Genzyme
Read More
Other News To Note
Read More
Appointments And Advancements
Read More